Evaluation of Pain Treatment After Total Knee Arthroplasty
RecruitingPhase 4
A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.
About the study
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
What is being tested
- Suzetrigine (drug)
- Placebo (drug)
Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 60 · Started: Apr 24, 2026
Contact the study team
- Medical Information · Phone: 617-341-6777
Official record on ClinicalTrials.gov — NCT07538570
Locations in the U.S.
| Texas | Legent Orthopedic and Spine Hospital, Bellaire Memorial Hermann Village Office, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.